Enobosarm: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •5 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
Enobosarm has not been approved by the FDA or any regulatory authority for any indication. Clinical development is ongoing. Long-term safety with chronic use in the obesity setting is not established.
ALT elevations have been documented in 6.7-20.8% of clinical trial participants depending on dose and population. While mostly transient, one case required treatment discontinuation. Periodic liver monitoring is essential.
Enobosarm suppresses testosterone, SHBG, LH, and FSH. While milder than anabolic steroids, the long-term consequences of chronic androgen axis suppression during obesity treatment are unknown.
Ostarine/MK-2866 sold online as supplements or research chemicals is not pharmaceutical-grade. The FDA has issued warning letters to companies selling SARMs. These products may contain contaminants, incorrect doses, or undisclosed substances and pose significant health risks.
Enobosarm/Ostarine is banned by WADA and all major sporting organizations as a prohibited anabolic agent (added to Prohibited List in 2008). Use may result in sanctions even from inadvertent exposure via contaminated supplements.
⚠️Important Warnings
- •'Investigational drug: Enobosarm is not approved for any indication. Use only within authorized clinical trials.'
- •'Unregulated products: Ostarine/MK-2866 products sold online are not pharmaceutical-grade and may contain dangerous contaminants. The FDA has issued multiple warning letters to SARM sellers.'
- •'Anti-doping violation: Ostarine is WADA-prohibited. Athletes may test positive even from inadvertent exposure through contaminated supplements.'
- •'Liver monitoring: ALT elevations have been documented. Liver function tests should be monitored at baseline and periodically during any clinical trial participation.'
- •'Hormonal effects: Enobosarm suppresses testosterone, SHBG, and gonadotropins. Consult a physician regarding hormonal monitoring.'
- •'Pregnancy: Androgen receptor modulation may cause fetal harm. Enobosarm must not be used during pregnancy or breastfeeding.'
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Not FDA-approved. FDA confirmed acceptable dosage (3 mg) and approval pathway for obesity/muscle preservation indication. Not legally available as a supplement or drug. FDA has issued warning letters to companies selling SARMs including Ostarine (December 2025). |
| European Union | Investigational | Not EMA-approved. SARMs are not authorized as pharmaceuticals or dietary supplements in the EU. |
| International (Sport) | Prohibited | Banned by WADA since 2008 as an anabolic agent. Prohibited by all major sporting organizations including IOC, USADA, NCAA, and professional sports leagues. |
| International (General) | Investigational | Not approved in any jurisdiction. Legal status of non-pharmaceutical SARM products varies by country. In many jurisdictions, SARMs occupy a regulatory gray area between supplements and controlled substances. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 500+ community reports
View community protocolsCritical Safety Information#
Enobosarm (Ostarine, GTx-024, MK-2866) is an investigational selective androgen receptor modulator that has not been approved by any regulatory authority. It is important to distinguish between pharmaceutical-grade enobosarm used in clinical trials and unregulated "Ostarine" products sold online, which pose significantly greater risks.
Investigational Status#
The primary risk of enobosarm is the uncertainty inherent to investigational drugs:
- Limited obesity data: The QUALITY trial was 16 weeks; long-term safety in the obesity setting requires 72-week PLATEAU data
- Failed Phase 3 in cancer: The POWER trials did not meet co-primary endpoints, though this reflects the cancer cachexia indication rather than the drug's pharmacological profile
- No long-term data: Effects of chronic SARM use on cardiovascular health, bone metabolism, endocrine function, and hepatic health beyond trial durations are unknown
- Regulatory path ongoing: FDA has confirmed an acceptable pathway but approval requires successful Phase 3 completion
Liver Risk#
Liver enzyme elevation is the most significant pharmacological risk:
- ALT elevations in 6.7% (elderly Phase 2) to 20.8% (cancer Phase 2 at 3 mg)
- Most elevations were transient and resolved while continuing treatment
- One case required discontinuation (ALT 4.2x ULN); normalized after stopping
- Published case reports of liver injury from non-pharmaceutical "Ostarine" products exist, potentially reflecting contaminated or mislabeled products
Monitoring: Liver function tests (ALT, AST, bilirubin) at baseline and periodically during treatment are essential for any clinical use.
Hormonal Suppression Risk#
Enobosarm suppresses the hypothalamic-pituitary-gonadal axis:
| Hormone | Effect | Clinical Significance |
|---|---|---|
| Testosterone (men) | Decreased | Potential hypogonadal symptoms with chronic use |
| SHBG | Significantly decreased (P<0.001) | Alters free hormone balance |
| LH (women) | Decreased | Hypothalamic suppression |
| FSH (women) | Decreased | Gonadotropin suppression |
While milder than the suppression caused by anabolic steroids, the consequences of chronic suppression during long-term obesity treatment (potentially years) are not known.
Unregulated Product Risks#
This is a critical safety concern. "Ostarine" or "MK-2866" products sold online carry unique risks:
- Not pharmaceutical-grade: Quality, purity, and dose accuracy are not verified
- Contamination: May contain undisclosed active substances, heavy metals, or other contaminants
- Mislabeling: Actual content may differ from label claims
- No medical oversight: Purchased without prescription or medical monitoring
- FDA warning letters: The FDA issued warning letters to SARM sellers in December 2025, finding products marketed as SARMs including Ostarine
- Health risks: The FDA warns of increased risk of stroke, liver damage, and heart attack from SARM products
Anti-Doping Considerations#
Ostarine is one of the most commonly detected prohibited substances in anti-doping testing:
- WADA status: Banned since 2008 under S1.2 (Other Anabolic Agents)
- Detection window: Can be detected in urine for weeks after exposure
- Contamination risk: Multiple athletes have tested positive from contaminated supplements not listing Ostarine on the label
- Applicable organizations: WADA, IOC, USADA, NCAA, UFC, NFL, NBA, MLB, and all major sports bodies
- Consequences: Positive tests result in competition bans regardless of intent
Regulatory and Legal Status#
| Jurisdiction | Status | Key Details |
|---|---|---|
| United States (FDA) | Investigational | Not approved; FDA confirmed approval pathway; warning letters issued to SARM sellers |
| European Union (EMA) | Investigational | Not approved as pharmaceutical or supplement |
| WADA | Prohibited | Banned anabolic agent since 2008 |
| International | Variable | Legal status of non-pharmaceutical SARMs varies by country |
Risk-Benefit Context#
Potential benefits (in clinical trial setting):
- 71% reduction in lean mass loss during GLP-1 therapy (QUALITY trial)
- Oral convenience vs injectable muscle-preserving therapies
- FDA-confirmed approval pathway
- No increase in GI adverse events when added to semaglutide
- Prevents physical function decline during weight loss
Current risks:
- Investigational status with limited long-term safety data
- Liver enzyme elevations requiring monitoring
- Hormonal suppression with unknown chronic consequences
- Failed Phase 3 in a different indication
- Significant risks from unregulated market products
- Anti-doping violation for athletes
Medical Disclaimer#
This information is provided for educational purposes only. Enobosarm is an investigational drug not approved for any use. Products marketed as "Ostarine" or "MK-2866" from non-pharmaceutical sources are not equivalent to clinical trial-grade enobosarm and carry significant safety risks. The FDA has explicitly warned against the use of SARMs obtained outside clinical trials. This content does not constitute medical advice or encouragement to obtain or use enobosarm in any form.
Related Reading#
Frequently Asked Questions About Enobosarm
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.